Elevated CD99 expression, especially in high-risk BCP-ALL subtypes with BCR-ABL1 and CRLF2 mutations, correlates with poor prognostic factors such as relapse, higher MRD positivity by day 29, and reduced overall survival [33]. Here, CRLF2 is linked to acute lymphoblastic leukemia.